2.Recent advances in the quantification of drug metabolizing enzymes and transporters by proteomic approach.
Bo YANG ; Jing WANG ; Yu-ting CONG ; Liang-hai HU ; Jing-kai GU
Acta Pharmaceutica Sinica 2015;50(6):668-674
With the advance of drug development and research techniques, the drug metabolic processes and mechanism can be more deeply achieved. As the drug metabolism and pharmacokinetics process are mediated by drug metabolizing enzymes and transporters, study of drug metabolizing enzymes and transporters has become an important part for drug development. The traditional immunoassays with low sensitivity and poor specificity can not reflect the accurate expression level of drug metabolizing enzymes and transporters. We now give a brief review on the quantitative study of drug metabolizing enzymes and transporters by mass spectrometry-based proteomic approach.
Enzymes
;
chemistry
;
Humans
;
Inactivation, Metabolic
;
Mass Spectrometry
;
Membrane Transport Proteins
;
chemistry
;
Pharmacokinetics
;
Proteomics
4.A review of the expression and activity of drug metabolism enzymes in tumorous cells.
Wen-jing XIAO ; Guang-ji WANG ; Ji-ye A
Acta Pharmaceutica Sinica 2014;49(10):1377-1386
Tumorous cells are characterized by distinctive metabolic reprogramming and living conditions. Understanding drug metabolizing features in tumor cells will not only favor the estimation of metabolic rate, elimination half life and the assessment of potency, but also facilitate the optimal design of anti-tumor drugs/prodrugs. This article reviewed the expression and activity features of major drug metabolizing enzymes (DMEs) in solid tumorous tissues, such as liver, intestine, breast and lung, and the difference from the correspondingly normal tissues, exemplified by the metabolic properties of some classic antitumor-agents in tumorous tissues. In combination with the data retrieved in vitro tumor cell lines, we discussed the similarities and differences of DMEs expression and function between tumor tissues (in vivo) and tumor cells (in vitro), and proposed the possible factors that cause the differences.
Antineoplastic Agents
;
pharmacokinetics
;
Cell Line, Tumor
;
Humans
;
Inactivation, Metabolic
;
Liver
;
metabolism
;
Neoplasms
;
enzymology
;
Prodrugs
;
pharmacokinetics
5.Recent advances in metabolism-based drug-drug interactions.
Yan-qing LIU ; Yan-jun HONG ; Su ZENG
Journal of Zhejiang University. Medical sciences 2009;38(2):215-224
The pharmacological or toxicological efficacy of drugs can be influenced significantly when their metabolic pathway is induced or inhibited by co-administrated drugs.Metabolism-based drug-drug interactions (DDIs) have a high incidence and are important in clinical therapeutics. Studies on metabolism-based DDIs are now moved to the early stages of drug development, so that adequate assessment of its safety and effectiveness can be facilitated. These studies comprise in vitro and in vivo investigations and an appropriate design of studies is important. In many cases, negative findings from early in vitro and early clinical studies can eliminate the need for later clinical investigations. This article summarizes the background and mechanism of metabolism-based DDIs and focuses on the strategies of these studies.
Drug Interactions
;
Drug-Related Side Effects and Adverse Reactions
;
Humans
;
Inactivation, Metabolic
;
Pharmaceutical Preparations
;
metabolism
6.The toxicological mechanisms and detoxification of depleted uranium exposure.
Yong-Chao YUE ; Ming-Hua LI ; Hai-Bo WANG ; Bang-Le ZHANG ; Wei HE
Environmental Health and Preventive Medicine 2018;23(1):18-18
Depleted uranium (DU) has been widely applied in industrial and military activities, and is often obtained from producing fuel for nuclear reactors. DU may be released into the environment, polluting air, soil, and water, and is considered to exert both radiological and chemical toxicity. In humans and animals, DU can induce multiple health effects, such as renal tubular necrosis and bone malignancies. This review summarizes the known information on DU's routes of entry, mechanisms of toxicity, and health effects. In addition, we survey the chelating agents used in ameliorating DU toxicity.
Animals
;
Chelating Agents
;
pharmacology
;
Humans
;
Inactivation, Metabolic
;
Radiation-Protective Agents
;
pharmacology
;
Uranium
;
metabolism
;
toxicity
7.Advance in cytochrome P450 1A2.
Journal of Central South University(Medical Sciences) 2008;33(5):456-460
CYP1A2 is an important cytochrome P450 enzymes, which is involved in metabolism of many clinical drugs and activation of some precarcinogens. CYP1A2 activity can be influenced by various factors including genetic polymorphism, drugs, food and so on, in which the CYP1A2 genetic polymorphism is the basis of difference on the activity and induction of CYP1A2. Therefore,the genotyping of CYP1A2 plays an important part in individualization of therapy.
Carcinogens
;
metabolism
;
Cytochrome P-450 CYP1A2
;
genetics
;
metabolism
;
Genotype
;
Humans
;
Inactivation, Metabolic
;
genetics
;
Polymorphism, Genetic
;
genetics
8.Effects of xuefu zhuyu decoction on antioxidant and drug-metabolizing enzymes in liver of rats.
Xing-hua FAN ; Wei-Zhou SHI ; Yun-xiang CHENG ; Kai-jie ZOU ; Xiu-fen YANG
China Journal of Chinese Materia Medica 2014;39(22):4453-4458
Xuefu Zhuyu decoction (XFZYD) is a famous traditional Chinese medicine (TCM) formula, is widely used in the treatment of cardiovascular and cerebrovascular diseases in China over one hundred years. But its effect on antioxidant and drug-metabolizing enzymes are unknown. This study was to observe the effects of Xuefu Zhuyu decoction (XFZYD) on the activities of antioxidant and drug metabolism enzymes (DMEs) in liver of rats. Male SD rats, treated with XFZYD at the dosage of 3.51, 7.02 and 14.04 g x kg(-1) per day for 15 days, serum were collected, tissue fluid, cytosols and microsomes isolated from liver tissues were prepared by centrifugation according to the standard procedure, the activities of antioxidant enzymes and drug-Metabolizing Enzymes were determined by UV-V is spectrophotometer. In serum, the activities of AST was not significantly affected by the treatment with XFZYD, at the high- est dose, the levels of ALT, Cr and BUN were significantly decreased (P < 0.05). GPX were significantly increased at the dose of 7.02, 14.04 g x kg(-1) (P < 0.05), CAT were significantly increased at the highest dose (P < 0.05). T-SOD was not significantly af- fected by this treatment. In the liver tissue, GPX was significantly increased at the dose of 3.51, 7.02 g x kg(-1) (P < 0.05), GST, CAT and T-SOD were not significantly affected following this treatment. In cytosols, GST was significantly increased at the dose of 3.51 g x kg(-1) (P < 0.05), T-SOD was remarkable induced at the dose of 3.51 and 7.02 g x kg(-1) (P < 0.05). In microsomes, XFZYD had no significant effect on Cytochromeb5, NADPH-Cytochrome P450 reductase, CYP3A, CYP2E1 and UGT, XFZYD significantly in- duced GST at the dose of 3.51 and 7.02 g x kg(-1) (P < 0.05), and the level of GSH were significantly increased by XFZYD at the dose of 3.51, 7.02 and 14.04 g kg(-1) (P < 0.05). These findings suggest XFZYD can induce the activities of GPX, CAT, SOD, GST and increase GSH level in liver of rats, which indicate XFZYD may have detoxification and antioxidant functions.
Animals
;
Antioxidants
;
metabolism
;
Drugs, Chinese Herbal
;
pharmacology
;
Inactivation, Metabolic
;
drug effects
;
Liver
;
drug effects
;
enzymology
;
Male
;
Rats
;
Rats, Sprague-Dawley
9.Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice.
Ling-juan CAO ; Miao YAN ; Huan-de LI ; Bi-kui ZHANG ; Ping-fei FANG
China Journal of Chinese Materia Medica 2015;40(13):2537-2541
Tripterygium wilfordii has exihibited multiple pharmacological activities, such as anti-inflammatory, immune modulation, anti-tumor and anti-fertility. T. wilfordii have been used for the therapy of inflammation and autoimmune diseases including rheumatoid arthritis, immune complex nephritis and systemic lupus erythematosus clinically. However, it is well known that T. wilfordii has small margin between the therapeutic and toxic doses and could cause serious injury on digestive, reproductive and urogenital systems. Among all the organs, liver is one of the most remarkable targets of T. wilfordii-induced toxicities, and the damage is more serious than others. It is generally accepted that T. wilfordii-induced liver injury is a result of the combined effects of toxic elements of T. wilfordii. It is reported in several studies that the mechanism of T. wilfordii-induced liver injury may be related to lipid peroxidation, cell apoptosis and immune damage, and so on. Licorice is one of the most commonly used Chinese herbal medicine, with effects of heat- clearing and detoxicating, anti-inflammatory and hepatoprotective, reconciling various drugs, and so on. Licorice often accompany T. wilfordii in clinical application which can significantly reduce the liver injury induced by T. wilfordii. The attenuated effect is exact, but the mechanism is still a lack of in-depth study. This paper reviews the studies on T. wilfordii-induced liver injury and the related mechanism as well as licorice and other traditional Chinese medicine accompany T. wilfordii to reduce the injury in recent years, so as to provide reference for related research in the future.
Animals
;
Chemical and Drug Induced Liver Injury
;
etiology
;
prevention & control
;
Glycyrrhiza
;
Humans
;
Inactivation, Metabolic
;
Medicine, Chinese Traditional
;
Tripterygium
10.Influence of phenobarbital and carbon tetrachloride on the modulation of tissue retention profile of hexachlorocyclohexane in rats.
Ravindra N KHANNA ; Mukul DAS ; Mohini ANAND
Biomedical and Environmental Sciences 2002;15(2):119-129
The study was designed to investigate the role of hepatic metabolic activity on body burden of HCH residue. Male albino rats were orally administered 0, 5, and 10 mg/kg HCH for 90 days, followed by either sodium phenobarbital or carbon tetrachloride treatment for 0, 15 and 30 days after withdrawal of their respective HCH administration. The liver weight was significantly increased at 30 days after the administration of phenobarbital and carbon tetrachloride in both 5 mg and 10 mg/kg HCH withdrawal groups when compared to control. HCH residue was maximum in fat followed by adrenal > thymus > liver > kidney > spleen > tests > brain > plasma. Carbon tetrachloride caused an accumulation of HCH residues in the liver 15 and 30 days after administration of both doses of HCH. Phenobarbital did not show significant variation in HCH residues in hepatic tissue. Phenobarbital treatment caused significant induction of hepatic RED, APD, AHH, GST and QR activities. Significant decreases in activities were observed by carbon tetrachloride when compared to animals treated with HCH alone. The overall results clearly suggest the role of P450 protein on the body burden of HCH residues.
Animals
;
Carbon Tetrachloride
;
toxicity
;
Inactivation, Metabolic
;
Lindane
;
pharmacokinetics
;
toxicity
;
Liver
;
enzymology
;
metabolism
;
pathology
;
Liver Function Tests
;
Male
;
Organ Size
;
drug effects
;
Phenobarbital
;
toxicity
;
Rats
;
Tissue Distribution